Kuopio Research Centre of Geriatric Care, University of Eastern Finland, Kuopio, Finland.
School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
J Alzheimers Dis. 2019;68(1):127-136. doi: 10.3233/JAD-180912.
Antiepileptic drugs (AEDs) have sedative properties which may lead to an increased risk of pneumonia.
To investigate whether incident AED use is associated with an increased risk of pneumonia among community-dwelling persons with Alzheimer's disease (AD). In addition, we determined the risk according to duration of AED use and specific AEDs.
Persons with AD were identified from the MEDALZ dataset which includes all community-dwelling persons who received a clinically verified diagnosis of AD during 2005-2011 in Finland (N=70,718). New AED users were identified with one-year washout period. A matched cohort (1 : 1, N=5,769, matching criteria age, gender, and time since AD diagnoses) of nonusers was formed. Data from nationwide registers included dispensed medications which were modelled with PRE2DUP method, hospitalizations, and causes of death. The association between AED use and hospital admission or death due to pneumonia was analyzed with Cox proportional hazard models.
AED use was associated with an increased risk of pneumonia (adjusted HR 1.92, 95% CI 1.63-2.26; incidence rate per 100 person-years 12.58, 95% CI 12.49-12.66 during AED use and 6.41, 95% CI 6.37-6.45 during nonuse). The highest risk was observed during the first month of use (aHR 3.59, 95% CI 2.29-5.61) and the risk remained elevated until two years of use. Of specific drug substances, phenytoin, carbamazepine, valproic acid, and pregabalin were associated with an increased risk.
Antiepileptic drug use may increase the risk of pneumonia which is concerning as persons with AD have elevated risk of pneumonia.
抗癫痫药物(AEDs)具有镇静作用,可能会增加患肺炎的风险。
研究社区居住的阿尔茨海默病(AD)患者中,新发 AED 使用是否与肺炎风险增加相关。此外,我们还根据 AED 使用时间和特定 AED 确定了风险。
AD 患者是从 MEDALZ 数据集确定的,该数据集包含芬兰 2005-2011 年期间所有接受过临床确诊 AD 的社区居住者(N=70718)。使用一年洗脱期确定新的 AED 使用者。形成了一个非使用者的匹配队列(1:1,N=5769,匹配标准为年龄、性别和 AD 诊断后时间)。全国性登记册中的数据包括经 PRE2DUP 方法建模的配药、住院和死因。使用 Cox 比例风险模型分析 AED 使用与肺炎住院或死亡的相关性。
AED 使用与肺炎风险增加相关(调整后的 HR 1.92,95%CI 1.63-2.26;AED 使用期间每 100 人年的发病率为 12.58,95%CI 12.49-12.66,非使用期间为 6.41,95%CI 6.37-6.45)。使用的第一个月风险最高(aHR 3.59,95%CI 2.29-5.61),并且风险持续到使用两年。特定药物中,苯妥英、卡马西平、丙戊酸和普瑞巴林与风险增加相关。
AED 使用可能会增加肺炎的风险,这令人担忧,因为 AD 患者肺炎风险增加。